Celcuity to Announce Q1 2024 Financial Results and Host Webcast/Call

Celcuity Inc., a clinical-stage biotechnology company listed on Nasdaq under the ticker CELC, is set to release its financial results for the first quarter of 2024. The announcement will be made after market close on Wednesday, May 15, 2024. Following the release, Celcuity's management will host a webcast and teleconference at 4:30 p.m. Eastern Time to discuss the financial outcomes and provide a corporate update.

Interested participants in the teleconference can join by dialing specific numbers: 1-888-886-7786 for domestic callers and 1-416-764-8658 for international callers. The webcast can be accessed live via a provided weblink, and a replay of the event will be available on Celcuity’s official website.

Celcuity is devoted to developing targeted therapies for treating various solid tumor cancers. The company’s primary therapeutic candidate is gedatolisib, a comprehensive inhibitor of both PI3K and mTOR. This candidate is notable for its distinct mechanism of action and pharmacokinetic properties, setting it apart from other therapies that target PI3K or mTOR individually or in combination.

The company is actively conducting a Phase 3 clinical trial known as VIKTORIA-1. This trial is assessing the efficacy of gedatolisib in combination with fulvestrant, with or without palbociclib, in patients who have HR+/HER2- advanced breast cancer. Recruitment for this study is ongoing, and more details can be found on ClinicalTrials.gov.

Additionally, Celcuity is running a Phase 1b/2 clinical trial named CELC-G-201. This trial is evaluating the combination of gedatolisib and darolutamide in patients with metastatic castration-resistant prostate cancer, and it is currently enrolling participants.

Celcuity has also developed the CELsignia companion diagnostic platform, which is a unique tool that can analyze live patient tumor cells. This platform identifies new groups of cancer patients who are likely to benefit from already approved targeted therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!